Atezolizumab

Generic Name: Atezolizumab

Brand Names: Tecentriq

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1380723-44-3

Unique Ingredient Identifier: 52CMI0WC3Y

Background: Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was grante...

Indication: Atezolizumab has approved indications for the following conditions:

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Hepatocellular Carcinoma (HCC)

Melanoma

Alveolar Soft Part Sarcoma (ASPS)

Associated Conditions: Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma

Associated Therapies: -

Clinical Trials

Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC

Phase 2

Recruiting

Conditions: NSCLC

Interventions: Drug: Atezolizumab
Drug: Tiragolumab

First Posted Date: 2023-04-04

Last Posted Date: 2024-12-09

Lead Sponsor: Alliance Foundation Trials, LLC.

Target Recruit Count: 178

Registration Number: NCT05798663

Locations: 🇺🇸
University of California San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
Washington University Siteman Cancer Center, Saint Louis, Missouri, United States
🇺🇸
Missouri Baptist Medical Center, Saint Louis, Missouri, United States

and more 4 locations

Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients with Advanced NSCLC Progressing After Immunotherapy & Chemotherapy

Phase 2

Active, not recruiting

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Paclitaxel
Drug: Bevacizumab
Drug: Atezolizumab

First Posted Date: 2023-03-23

Last Posted Date: 2024-10-11

Lead Sponsor: Intergroupe Francophone de Cancerologie Thoracique

Target Recruit Count: 156

Registration Number: NCT05781308

Locations: 🇫🇷
CHU Amiens, Amiens, France
🇫🇷
CHU Besançon - Hôpital J. MINJOZ, Besançon, France
🇫🇷
Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France

and more 41 locations

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

Phase 2

Recruiting

Conditions: Neoplasms by Site
Cancer
Melanoma
Colorectal Neoplasms
Malignancy
Lymphoproliferative Disorders
Endometrial Neoplasms
Malignant Neoplasm
Neoplasms by Histologic Type

Interventions: Drug: Atezolizumab

First Posted Date: 2023-03-15

Last Posted Date: 2024-01-05

Lead Sponsor: Cancer Research UK

Target Recruit Count: 30

Registration Number: NCT05770102

Locations: 🇬🇧
Velindre Cancer Centre, Cardiff, United Kingdom
🇬🇧
Royal Hospital for Children Glasgow, Glasgow, United Kingdom
🇬🇧
Weston Park Hospital, Sheffield, United Kingdom

and more 23 locations

Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma

Phase 1

Recruiting

Conditions: Malignant Pleural Mesothelioma

Interventions: Biological: Dendritic cell vaccination
Drug: Atezolizumab
Drug: Platinum/pemetrexed based chemotherapy

First Posted Date: 2023-03-13

Last Posted Date: 2024-05-16

Lead Sponsor: University Hospital, Antwerp

Target Recruit Count: 15

Registration Number: NCT05765084

Locations: 🇧🇪
Antwerp University Hospital, Edegem, Antwerp, Belgium
🇧🇪
VITAZ, Sint-Niklaas, Belgium
🇧🇪
AZ Maria Middelares, Ghent, Belgium

Tiragolumab and Atezolizumab in Patients with Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

Phase 2

Active, not recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Tiragolumab
Drug: Atezolizumab
Drug: Pemetrexed
Drug: Carboplatin

First Posted Date: 2023-02-27

Last Posted Date: 2024-12-16

Lead Sponsor: Liza Villaruz, MD

Target Recruit Count: 3

Registration Number: NCT05746481

Locations: 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Biological: RP2
Biological: Bevacizumab
Biological: Atezolizumab

First Posted Date: 2023-02-17

Last Posted Date: 2024-11-20

Lead Sponsor: Replimune Inc.

Target Recruit Count: 60

Registration Number: NCT05733598

Locations: 🇺🇸
University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

and more 1 locations

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Phase 2

Recruiting

Conditions: Haematological Malignancy
Solid Tumor

Interventions: Drug: Trastuzumab in combination with pertuzumab
Drug: Vemurafenib in combination with cobimetinib
Drug: Alectinib
Drug: Atezolizumab
Drug: Entrectinib

First Posted Date: 2023-02-10

Last Posted Date: 2024-03-20

Lead Sponsor: Cancer Research UK

Target Recruit Count: 825

Registration Number: NCT05722886

Locations: 🇬🇧
Belfast City Hospital, Belfast, United Kingdom
🇬🇧
Bristol Royal Hospital for Children, Bristol, United Kingdom
🇬🇧
The Beatson Hospital, Glasgow, United Kingdom

and more 22 locations

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

Phase 2

Recruiting

Conditions: Advanced Rare Malignant Solid Neoplasm
Rare Malignant Solid Neoplasm
Refractory Rare Malignant Solid Neoplasm

Interventions: Biological: Atezolizumab
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Echocardiography
Drug: Tiragolumab

First Posted Date: 2023-02-08

Last Posted Date: 2024-11-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT05715281

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States